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BACKGROUND: Well- conducted meta- analyses are considered to be at the top of the evidence- based hierarchy pyramid, with 
an expansion of these publications within the cardiovascular research arena. There are limited data evaluating the trends and 
quality of such publications. The objective of this study was to evaluate the methodological rigor and temporal trends of car-
diovascular medicine- related meta- analyses published in the highest impact journals.
METHODS AND RESULTS: Using the Medline database, we retrieved cardiovascular medicine- related systematic reviews and 
meta- analyses published in The New England Journal of Medicine, The Lancet, Journal of the American Medical Association, 
The British Medical Journal, Annals of Internal Medicine, Circulation, European Heart Journal, and Journal of American College 
of Cardiology between January 1, 2012 and December 31, 2018. Among 6406 original investigations published during the study 
period, meta- analyses represented 422 (6.6%) articles, with an annual decline in the proportion of published meta- analyses 
(8.7% in 2012 versus 4.6% in 2018, Ptrend=0.002). A substantial number of studies failed to incorporate elements of Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses or Meta- Analysis of Observational Studies in Epidemiology guide-
lines (51.9%) and only a minority of studies (10.4%) were registered in PROSPERO (International Prospective Register of 
Systematic Reviews). Fewer manuscripts failed to incorporate the Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses or Meta- Analysis of Observational Studies in Epidemiology elements over time (60.2% in 2012 versus 40.0% 
in 2018, Ptrend<0.001) whereas the number of meta- analyses registered at PROSPERO has increased (2.4% in 2013 versus 
17.5% in 2018, Ptrend<0.001).
CONCLUSIONS: The proportion of cardiovascular medicine- related meta- analyses published in the highest impact journals has 
declined over time. Although there is an increasing trend in compliance with quality- based guidelines, the overall compliance 
remains low.
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Well- conducted and rigorous systematic reviews and meta- analyses are considered to be the highest level of evidence and are positioned at 
the top of the evidence- based pyramid hierarchy.1 This 
is accomplished by identifying and combining relevant 
data to increase power, evaluating the risk of bias, 
identifying sources of variation, and rating the overall 
quality of existing evidence.2,3 The output of such stud-
ies carries the potential to augment existing data from 
randomized controlled trials (RCTs) and observational 
studies. Since their inception in the 1970s, there has 
been a tremendous upsurge in the number of sys-
tematic reviews and meta- analyses published each 
year.4- 6 Several factors have contributed to this trend 
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such as the technological advancements resulting in 
the ease of access to available databases and sim-
plified algorithm- based software to efficiently screen, 
synthesize, and accurately analyze large sets of data, 
as well as the rise in the production of well- conducted 
RCTs and the rapid evolution of the field. This expan-
sion in systematic reviews and meta- analyses has led 
to a dramatic increase in duplication of studies with 
identical subjects as well as fabrication of many dis-
organized, nonguideline adherent, and suboptimal- 
quality studies.2,5,7 Despite this global observation, 
there is a lack of objective data to study the trends in 
quality, proportion, and guideline concordance of the 
existing systematic reviews and meta- analyses within 
the realm of cardiovascular medicine. The objectives 
of this analysis were to evaluate trends of cardiovas-
cular medicine- related systematic reviews and meta- 
analyses published in highest impact journals with 
regards to their methodological quality, relative propor-
tion to original investigations, and adherence to recom-
mended guidelines for conducting systematic reviews 
and meta- analyses.
METHODS
The authors declare that all supporting data are avail-
able within the article and the online supplementary 
files. This study was exempted from institutional review 
board because this is a study- level analysis.
Search Strategy and Study Selection 
Criteria
Systematic reviews and meta- analyses published in 
the 8 highest Web of Science Impact Factor journals 
(according to Journal Citation Reports 2018: category 
“General Internal Medicine” and “Cardiology”) were in-
cluded. The following journals were included: The New 
England Journal of Medicine, The Lancet, Journal of 
the American Medical Association, The British Medical 
Journal, Annals of Internal Medicine, Circulation, 
European Heart Journal, and Journal of American 
College of Cardiology.8,9 The Medline database was 
used to identify meta- analyses and systematic reviews 
published between January 1, 2012 and December 31, 
2018. Systematic reviews that did not report any quan-
titative data synthesis were excluded. The retrieved ar-
ticles were manually screened based on the title and/
or abstract to identify cardiovascular medicine- related 
publications, which were the focus of this analysis. For 
each journal, we also identified the number of original 
investigation publications over the same period. Three 
investigators (D.M., A.T., and A.S.) worked indepen-
dently to extract the data. In case of discrepancies, 
the full text was reviewed by an independent investi-
gator (I.E.) along with the previous author to reach a 
consensus.
Data Extraction and Assessment of 
Methodological Quality
For each cardiovascular medicine- related article, we 
identified the following variables: year of publication, 
registration in PROSPERO (International Prospective 
Register of Systematic Reviews), change in the study 
protocol, type of meta- analysis (pairwise versus 
network), type of studies included (RCTs, observa-
tional trials, or both), data level (patient level versus 
study level), focus of the article, funding source (in-
dustry versus nonindustry), and access (open ver-
sus closed access). Furthermore, full- length articles 
were reviewed to assess the methodological quality 
of the systematic reviews and meta- analyses based 
on the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses (PRISMA) and Meta- 
Analysis of Observational Studies in Epidemiology 
(MOOSE) guidelines (Table S1).10,11 The quality of 
systematic reviews and meta- analyses was judged 
on the following factors: mention of “meta- analysis 
or systematic review” in the title, inclusion of a 
PRISMA flow diagram, assessment of risk bias, 
use of Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) assessment, 
assessment of publication bias if >10 studies, and 
CLINICAL PERSPECTIVE
What Is New?
• The number of cardiovascular medicine- related 
systematic reviews and meta- analyses pub-
lished in the highest impact journals has de-
creased over time.
• The overall compliance with the quality stand-
ards for systematic reviews and meta- analyses 
remains suboptimal.
What Are the Clinical Implications?
• Raising the awareness of these limitations and 
better adherence to respective guidelines would 
allow publication of only high- quality systematic 
reviews and meta- analyses.
Nonstandard Abbreviations and Acronyms
MOOSE Meta- Analysis of Observational Studies 
in Epidemiology
PRISMA Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses
RCT randomized controlled trial
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assessment of heterogeneity as well as exploration 
via subgroup, sensitivity, or metaregression analy-
ses if the degree of statistical heterogeneity was 
high. Heterogeneity was defined as being high if 
I2 statistic was >50%.12 The overall assessment of 
these variables for each included meta- analysis is 
reported in Table S2.
Statistical Analysis
We assessed the proportion of cardiovascular 
medicine- related systematic reviews and meta- 
analyses in relation to the overall number of original 
investigations published in the same journal dur-
ing the same publication year. After stratifying the 
publications by the year of publication, we com-
puted the percentage of systematic reviews and 
meta- analyses published as compared with original 
investigations. Subsequently, we assessed the tem-
poral trend in the ratio of published cardiovascular 
medicine- related systematic reviews and meta- 
analyses to original investigations. The distribution 
of the aforementioned variables was evaluated for 
all cardiovascular medicine- related systematic re-
views and meta- analyses. Chi- square test for linear 
trend was used to evaluate current temporal trends. 
The rates were expressed as a percentage and all 
P values were double sided. All categorical vari-
ables were reported as raw frequencies and overall 
percentages. All 2- sided P values were considered 
significant at the α=0.05 level. We used SAS ver-
sion 9.1.3 (SAS Institute, Inc., Cary, NC) and Stata 
version 14 (StataCorp, College Station, TX) for all 
analyses.
RESULTS
Included Meta- Analyses
The search identified 6406 original investigations pub-
lished during the study period in the journals reviewed, 
with meta- analyses representing 422 (6.6%) articles. 
The ratio of original investigations to systematic reviews 
and meta- analyses ratio was ≈14:1. The characteristics 
of the systematic reviews and meta- analyses are dis-
played in Table 1. Notably, a large proportion of stud-
ies were pairwise meta- analyses (91.7%), exclusively 
included RCTs (50.9%), and were nonindustry funded 
(50.5%). Patient- level meta- analyses comprised only 
a small proportion (16.6%) of all systemic reviews and 
meta- analyses.
Temporal Trends
During the study period, there was a decreasing 
trend in the number of published systematic re-
views and meta- analyses (68 studies in 2012 versus 
40 studies in 2018, Ptrend=0.006). Furthermore, we 
observed a decreasing trend in the proportion of 
cardiovascular medicine- related systematic reviews 
and meta- analyses to original investigations (8.7% in 
2012 versus 4.6% in 2018, Ptrend=0.002) (Figure  1). 
There was a decline in the proportion of systematic 
reviews and meta- analyses that did not follow the el-
ements of PRISMA or MOOSE guidelines (60.2% in 
2012 versus 40.0% in 2018, Ptrend<0.001) (Figure 2). 
The proportion of studies registered in PROSPERO 
demonstrated an increasing trend over time (2.4% in 
2013 [PROSPERO was launched in late 2011] versus 
17.5% in 2018, Ptrend<0.001) (Figure 3). Finally, there 
were no significant temporal change in the number 
of industry- funded studies (Ptrend=0.16), systematic 
reviews and meta- analyses consisting of only RCTs 
(Ptrend=0.92), and number of patient- level meta- 
analyses (Ptrend=0.43).
Table 1. Overall Characteristics of Cardiovascular 
Medicine−Related Systematic Reviews and Meta- Analyses
Cardiovascular medicine−related systematic 
reviews and meta- analyses
Studies 
(n=422)
Journal, n (%)
The New England Journal of Medicine 1 (0.2)
The Lancet 43 (10.2)
Journal of American Medical Association 20 (4.7)
British Medical Journal 71 (16.8)
Annals of Internal Medicine 44 (10.4)
Circulation 72 (17.1)
European Heart Journal 76 (18.0)
Journal of American College of Cardiology 95 (22.5)
Type of meta- analysis, n (%)
Pairwise 387 (91.7)
Network 35 (8.3)
Type of studies included, n (%)
Randomized controlled trials 215 (50.9)
Observational studies 120 (28.4)
Both 87 (20.6)
Level of meta- analysis, n (%)
Patient level 70 (16.6)
Study level 352 (83.4)
Focus of study, n (%)
Therapeutic 239 (56.6)
Epidemiology 89 (21.1)
Diagnostics 60 (14.2)
Other 49 (11.6)
Source of funding, n (%)
None 144 (34.1)
Industry 65 (15.4)
Nonindustry 213 (50.5)
Open access publication, n (%) 237 (56.2)
D
ow
nloaded from
 http://ahajournals.org by on O
ctober 6, 2021
J Am Heart Assoc. 2021;10:e021367. DOI: 10.1161/JAHA.121.021367 4
Mahtta et al Quality of Cardiovascular- Related Meta- Analyses
Assessment of Meta- Analyses Quality
Table 2 demonstrates the compliance of studies with 
guidelines for conducting high- quality systematic re-
views and meta- analyses. A substantial proportion 
(51.9%) of all systematic reviews and meta- analyses 
failed to incorporate MOOSE or PRISMA guidelines. 
The majority of systematic reviews and meta- analyses 
published did not include all PRISMA elements: flow 
diagram (66.6%), risk assessment of bias (53.1%), as-
sessment of heterogeneity (83.4%), exploration via sub-
group analyses or sensitivity analyses in cases of high 
heterogeneity (78.7%), and assessment of publication 
bias (54.3%). Registration in PROSPERO (10.4%) and 
use of GRADE assessment (7.1%) was incorporated by 
a small proportion of all systematic reviews and meta- 
analyses (Figure 1).
DISCUSSION
In this comprehensive analysis of cardiovascular 
medicine- related systematic reviews and meta- 
analyses, we demonstrated that approximately 1 in 
14 original investigations published in the 8 highest 
impact journals between 2012 and 2018 were meta- 
analyses. In addition, the proportion of systematic 
reviews and meta- analyses to original investigations 
has significantly decreased over time in these jour-
nals. Although there has been a significant rise in the 
Figure 1. Temporal trend in proportion of published systematic reviews and meta- analyses and their methodological rigor.
A, Proportion of cardiovascular related systematic reviews and meta- analyses to original investigations were calculated and stratified 
by the year of publication. Trend analysis was conducted to depict P- trend. B, Frequency of methodological rigor was calculated 
based on compliance with various elements of PRISMA and MOOSE guidelines as well as PROSPERO registration. GRADE indicates 
Grading of Recommendations Assessment, Development and Evaluation; MOOSE, Meta- Analysis of Observational Studies in 
Epidemiology; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta- Analyses; and PROSPERO, International 
Prospective Register of Systematic Reviews.
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proportion of systematic reviews and meta- analyses 
registered in PROSPERO, the overall percentage of 
systematic reviews and meta- analyses registered 
in PROSPERO remains small (~10%). Similarly, al-
though we observed an increasing temporal trend 
in the incorporation of elements from PRISMA or 
MOOSE guidelines, a greater proportion of cardio-
vascular systematic reviews and meta- analyses did 
not comply with all domains of PRISMA or MOOSE 
guidelines.
In light of recent technological advancements 
including ease of access to large publicly acces-
sible databases and software with capabilities to 
screen and analyze prior publications,13 together 
with the rapidly expanding base of RCTs, there has 
been a high level of interest in generating system-
atic reviews and meta- analyses by various inves-
tigator groups. Accordingly, the clinical research 
community has criticized and voiced mixed feelings 
toward the quality of this burgeoning expansion of 
systematic reviews and meta- analyses.2,3,5,7 In this 
analysis, which focused only on the highest impact 
journals as defined by impact factor, we observed 
a decreasing trend in published systematic reviews 
and meta- analyses. This trend observed is in stark 
contrast to the previously reported uptrend in other 
specialties.4,14 This might be attributed to several 
factors. Editors and reviewers of these highest im-
pact journals may curtail the number of systematic 
reviews and meta- analyses that successfully pass 
the peer- review process. Moreover, evidence- based 
medicine in the cardiovascular community has been 
primarily driven by large RCTs and high- quality ob-
servational studies. The fact that systematic reviews 
and meta- analyses mostly confirm the findings of 
these high- quality original investigations by providing 
more refined estimates to the effect size may prohibit 
their uptake in these high- impact journals. Finally, a 
potential redundancy in data and suboptimal com-
pliance with quality standards may predispose the 
authors of non- high- quality systematic reviews and 
meta- analyses to avoid submission to these high- 
impact journals.15,16
This study demonstrated that a significant proportion 
of cardiovascular medicine- related systematic reviews 
and meta- analyses published in high- impact journals did 
not adequately fulfill guideline recommended elements 
of publishing high- quality systematic reviews and meta- 
analyses (ie, PRISMA or MOOSE guidelines). Compliance 
with elements such as the use of GRADE assessment, 
incorporation of a flow diagram, and assessment of risk 
bias and publication bias remained particularly low. Our 
findings, which highlight the suboptimal compliance with 
PRISMA and MOOSE guidelines, are in line with what 
has been previously demonstrated in other clinical areas 
of research.17- 20 These investigations have reported a 
compliance rate of as low as 50% with PRISMA and 
MOOSE guidelines among systematic reviews and meta- 
analyses, a finding that is consistent with our results de-
spite the high- impact nature of our selected journals. We 
also observed that only a minority of the included meta- 
analyses reported the GRADE assessment. The steady 
Figure 2. Temporal trend among systematic reviews and meta- analyses failing to 
comply with PRISMA or MOOSE guideline elements.
Proportion of studies that did not incorporate PRISMA or MOOSE guideline elements were 
calculated and stratified by the year of publication. Trend analysis was conducted to depict 
P- trend. MOOSE indicates Meta- Analysis of Observational Studies in Epidemiology; and 
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta- Analyses.
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dissemination of these quality standards and guidelines 
can be attributed to the increasing temporal trend in the 
incorporation of these guideline elements as demon-
strated in our analysis.21,22 However, the continued sub-
optimal rates of compliance may be in part attributed to 
the lack of adoption of such guidelines by investigator 
groups. Additionally, lack of awareness by investigator 
groups and relying on methodology noted in prior high- 
impact journal publications rather than seeking out spe-
cific PRISMA and MOOSE guideline checklists may also 
propagate the manufacturing of suboptimal quality sys-
tematic reviews and meta- analyses.
An overall increase in the temporal trend of 
PROSPERO registration was also demonstrated by 
our analyses. Launched in 2011, the primary aim of 
PROSPERO is to provide transparency about ongo-
ing systematic reviews.23,24 Registration in PROSPERO 
serves to avoid unnecessary duplication of simi-
lar analyses, minimize reporting bias, and hold au-
thors accountable for reporting all prespecified end 
points.25,26 Therefore, registration in PROSPERO 
protects systematic reviews against biases that may 
otherwise dilute and discredit the reported results. 
A large- scale analysis by Page et al demonstrated a 
significant increase in registration of systematic re-
views in PROSPERO between 2011 and 2017.27 The 
authors demonstrated a roughly 10- fold increase in 
PROSPERO registration. Our results pertaining to 
cardiovascular medicine- related systematic reviews 
are in line with such observations. Despite this, it is 
noteworthy that among the overall published system-
atic reviews and meta- analyses, only 1 in 10 were 
registered in PROSPERO. Hence, although there 
has been an uptrend over time, the compliance with 
PROSPERO registration remains poor. Future investi-
gations evaluating barriers to PROSPERO registration 
are needed to fully understand the reasons behind 
our findings. Identifying such obstacles would help 
improve PROSPERO registration rates and thereby 
provide credible and high- quality systematic reviews to 
the research community.
This study has some limitations that are worth 
noting. First, additional information regarding overlap 
among systematic reviews and meta- analyses topics 
could not be ascertained in our study, but other stud-
ies have shown that there are concerns related to over-
lapping cardiovascular- related meta- analyses.7,15 We 
were unable to assess whether authorship guidelines 
of the included journals have evolved over time with 
regard to requiring adherence to qualitative guidelines 
and whether this has contributed to the observed trend 
in adherence to MOOSE and PRISMA guidelines. The 
results noted in our study may not be representative 
of noncardiovascular- related systematic reviews and 
meta- analyses or generalizable to lower impact car-
diovascular journals. Finally, we did not have to access 
Figure 3. Temporal trend in the proportion of published cardiovascular medicine- related systematic reviews and meta- 
analyses with PROSPERO registration.
Proportion of studies with PROSPERO registration were calculated and stratified by the year of publication. PROSPERO indicates 
International Prospective Register of Systematic Reviews.
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to the submission rates of meta- analyses among the 
included journals, which might contribute to the reduc-
tion in the number of published meta- analyses among 
the included journals.
CONCLUSIONS
The number of cardiovascular medicine- related sys-
tematic reviews and meta- analyses published in the 
Table 2. Compliance with Guidelines for Conducting High- Quality Systematic Reviews and Meta- Analyses
Guidelines- based quality 
metrics Relevance and definition Compliant studies, n (%)
PROSPERO (International Prospective Register of Systematic Reviews)
Registration PROSPERO is an international database of prospectively registered systematic reviews 
in health care. A permanent record of essential details of study protocol is maintained. 
Studies should be registered in PROSPERO at the protocol/inception stage and details 
should be entered to avoid unplanned duplication and to enable comparison between 
published methods and planned protocol. A lack of registration in PROSPERO may 
discredit a study because of the potential of subject duplication or modification of 
methods during data analysis stage.
44 (10.4%)
Change in PROSPERO 
protocol
A change in PROSPERO protocol refers to divergence from predefined methods 
or assessment of variables. A change in PROSPERO protocol without reasonable 
explanation may discredit a study.
3 (6.8%)
Preferred Reporting Items for Systematic Reviews and Meta- Analyses elements
Title indicates “Meta- 
analysis” or “Systematic 
Review”
Title should clearly identify the study as a systematic review, meta- analysis, or both. 
Without proper identification and transparency, the study may be perceived as an 
original investigation by the readership on a quick glance. A lack of proper title may 
result in misperceptions regarding the robustness of conclusions disseminated by the 
study.
343 (81.3)
Flow diagram provided A flow diagram should be provided with clear identification of methods used to acquire 
the study sample, procedure for screening studies, assessment of study eligibility, 
and the number of studies included in the analysis. The number of studies excluded 
and the reasons for exclusions should also be highlighted at each stage. Without such 
transparency displayed in a flow diagram, a systematic review or meta- analysis may 
lose credibility in their methodology of cohort creation.
281 (66.6)
Risk of bias assessed The risk of bias should be assessed in individual studies and across all the included 
studies. The investigators should specify assessment of such risk, whether this was 
performed at the study level or outcome level, and how it should be incorporated during 
data- interpretation of the cumulative evidence. Without a thorough assessment of risk 
bias, the results reported by cumulative systematic review or meta- analysis may lose 
credibility.
224 (53.1)
Use of GRADE assessment GRADE assessment developed by the Grading of Recommendation, Assessment, 
Development and Evaluation (GRADE) working group aims to grade quality of evidence 
and strength of recommendation presented by healthcare outcomes. This approach 
allows for a consistent method of assessing the quality of evidence for predefined 
outcomes across several studies. The quality of evidence is rated as high, moderate, 
low, or very low. All inclusive, this allows for a transparent judgment of the quality of 
evidence provided by the studies included in the systematic review or meta- analyses. 
Without GRADE assessment, the quality of evidence included in the systematic review 
or meta- analysis remains questionable and thereby decreasing the robustness of the 
conclusions drawn.
30 (7.1)
Assessment of 
heterogeneity
Heterogeneity refers to the variation in evaluated outcomes among the included studies. 
I2 statistic is often used to assess variation across studies with higher I2 indicative of 
higher variance in results that is attributable to heterogeneity in the studies included. 
Without assessment of heterogeneity, the estimation of the combined effect of studies 
included in the meta- analysis or systematic review is often discredited.
352 (83.4)
Exploration via subgroup 
analysis, sensitivity analysis, 
or meta- regression (if 
heterogeneity was high)
If heterogeneity across the studies included is high, further exploratory analyses (such 
as subgroup analysis, sensitivity analysis, or metaregression) must be performed to 
validate the results displayed by the systematic review or meta- analysis. Without a 
well- conducted exploratory analysis in the setting of high heterogeneity, the conclusions 
drawn by the study may not be validated.
277 (78.7)*
Assessment of publication 
bias (if >10 studies)
Publication bias refers to the higher likelihood of a study being published based on 
not only the quality of methodology, but also the hypothesis tested, significance, 
and directionality of results presented. This may result in studies supporting their 
hypothesis being published more often and faster as compared with studies refuting 
their hypothesis. Without evaluation of publication bias, the conclusions drawn by the 
systematic review or meta- analysis ought to be interpreted with caution.
216 (54.3)†
*277/352 (No of studies with further exploration in cases of high heterogeneity / # of studies with assessment of heterogeneity).
†216/398 (No of studies with assessment of publication bias / # of studies with analysis of >10 studies).
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highest impact journals has decreased over time. The 
proportion of these systematic reviews and meta- 
analyses to original articles published in such jour-
nals has also experienced a downtrend. The overall 
compliance with the quality standards for system-
atic reviews and meta- analyses remains suboptimal. 
Similarly, although PROSPERO registration for sys-
tematic reviews has increased over time, only 1 in 10 
cardiovascular medicine- related systematic reviews 
are registered in PROSPERO. High- quality system-
atic reviews and meta- analyses serve as an impor-
tant constituent of the wide range of methodological 
studies. Raising the awareness of these limitations 
and better adherence to respective guidelines would 
allow publication of only high- quality systematic re-
views and meta- analyses.
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Table S1. Meta-analysis of Observational Studies in Epidemiology (MOOSE) Checklist. 
Reporting of background should include: 
- Problem definition
- Hypothesis statement
- Description of study outcome(s)
- Type of exposure or intervention used
- Type of study designs used
- Study population
Reporting of search strategy should include: 
- Qualifications of searchers
- Search strategy, including time period included in the synthesis and keywords
- Effort to include all available studies, including contact with authors
- Databases and registries searched
- Search software used, name and version, including special features used
- Use of hand searching
- List of citations located and those excluded, including justification
- Method of addressing article published in languages other than English
- Method of handling abstracts and unpublished studies
- Description of any contact with authors
Reporting of methods should include: 
- Description of relevance or appropriateness of studies assembled for assessing the
hypothesis to be tested
- Rationale for the selection and coding of data
- Documentation of how data were classified and coded
- Assessment of confounding
- Assessment of study quality, including blinding of quality assessors, stratification or
regression on possible predictors of study results
- Assessment of heterogeneity
- Description of statistical methods in sufficient details to be replicated
- Provision of appropriate tables and graphics
Reporting of results should include: 
- Graphic summarizing individual study estimates and overall estimate
- Table giving descriptive information for each study included
- Results of sensitivity testing
- Indication of statistical uncertainty of findings
Reporting of discussion should include: 
- Quantitative assessment of bias
- Justification for exclusion
- Assessment of quality of included studies
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Reporting of conclusions should include: 
- Consideration of alternative explanations of observed results 
- Generalization of the conclusions  
- Guidelines for future research  
- Disclosure of funding source 
 
Table adapted from Stroup et al. JAMA 2000;283:2008-12. 
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Table S2. Individual assessment for each meta-analysis (see Excel file). 
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